Related Experiment Video

Updated: Mar 8, 2026

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

13.1K

MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients

Sajad Varmazyar1, Sayed Mahdi Marashi1, Zabihollah Shoja2

  • 1Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, 14155, Iran.

Medical Microbiology and Immunology
|January 14, 2017
PubMed

Insights

The MDM2 SNP309 genetic variation does not appear to increase Kaposi

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • The MDM2 gene's promoter region contains a single-nucleotide polymorphism (SNP309T>G, rs2279744).
  • This SNP is linked to elevated MDM2 protein expression in several cancers.
  • Limited research exists on the MDM2 SNP309's role in Kaposi's sarcoma (KS) development.

Purpose of the Study:

  • To investigate the association between the MDM2 SNP309 polymorphism and the risk of classic Kaposi's sarcoma (KS).
  • To explore potential correlations between MDM2 SNP309 genotype, gender, disease stage, and age at diagnosis in KS patients.

Main Methods:

  • Case-control study involving 79 Iranian patients with classic KS and 123 healthy controls.
  • Genotyping of the MDM2 SNP309 polymorphism using Polymerase Chain Reaction (PCR) and restriction fragment length polymorphism (RFLP) techniques.
  • Statistical analysis to assess the association between the polymorphism and KS risk, as well as clinical factors.

Main Results:

  • No significant association was found between the MDM2 SNP309 polymorphism and the overall risk of developing classic KS.
  • No significant correlation was observed between MDM2 SNP309 genotype, gender, or disease stage.
  • A significant association was identified between the SNP309 GG genotype and a younger age of onset (≤50 years) in KS patients (OR 9.5, P=0.03).

Conclusions:

  • The MDM2 SNP309 polymorphism does not appear to play a major role in the pathogenesis of Kaposi's sarcoma.
  • The MDM2 SNP309 GG genotype may be associated with an earlier onset of KS, suggesting a potential influence on clinical outcomes in younger individuals.
Keywords:
Kaposi’s sarcomaMDM2Risk factorSingle-nucleotide polymorphism

More Related Videos

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus09:53

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

9.4K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
77
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.8K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
51
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
303